ENHO and Obesity: Although adropin has been previously investigated in numerous animal and clinical studies as a biomarker of T2DM-induced nephropathy, endothelial dysfunction, arterial stiffening, and atherosclerosis [24,47,48,49], there are scarce studies regarding its predictive ability in the HF population with several concomitant diseases, including T2DM and obesity [50].